Premium
Prognostic impact of minimal residual disease at the end of consolidation in NCI standard‐risk B‐lymphoblastic leukemia: A report from the Children's Oncology Group
Author(s) -
Rau Rachel E.,
Dai Yunfeng,
Devidas Meenakshi,
Rabin Karen R.,
ZweidlerMcKay Patrick,
Angiolillo Anne,
Schore Reuven J.,
Burke Michael J.,
Salzer Wanda L.,
Heerema Nyla A.,
Carroll Andrew J.,
Winick Naomi J.,
Hunger Stephen P.,
Raetz Elizabeth A.,
Loh Mig L.,
Wood Brent L.,
Borowitz Michael J.
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28929
Subject(s) - medicine , minimal residual disease , oncology , lymphoblastic leukemia , cog , hematopoietic stem cell transplantation , overall survival , leukemia , disease , artificial intelligence , computer science
The 5‐year disease‐free survival (DFS) of National Cancer Institute (NCI) high‐risk (HR) B‐lymphoblastic leukemia (B‐ALL) patients with end of induction (EOI) minimal residual disease (MRD) ≥0.1% and end of consolidation (EOC) MRD ≥0.01% is 39 ± 7%, warranting consideration of hematopoietic stem cell transplant (HSCT). However, the impact of EOC MRD in NCI standard‐risk (SR) B‐ALL patients using COG regimens is unknown. We found that SR patients with MRD ≥0.01% at both EOI and EOC have a 4‐year DFS/overall survival (OS) of 72.9 ± 19.0%/91.7 ± 10.8% versus 90.7 ± 2.9%/95.5 ± 2.0% ( p = .0019/.25) for those with EOI MRD ≥0.01% and EOC MRD <0.01%. These data suggest that routine use of HSCT may not be warranted in EOC MRD ≥0.01% SR patients.